Coding and Reimbursement Updates
- This Month’s E-Reiumbursement Newsletter from Bobbi Buell contains updates on upcoming July HCPCS code changes, braces providers for chaotic 2027 ACA policy shifts that risk leaving patients uninsured mid-treatment, and highlights a discouraging AMA survey proving that prior authorization headaches and their adverse effects on patients remain stubbornly unresolved by AI.
Read More
Corporate Member News
- Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML.
Press Release Publication
- The Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Read More
- Updated 1L mTNBC recommendations from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer from Gilead Oncology
Read More
- The Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Read More
News from ASCO
- Standing Ovation Erupts at ASCO 2026 for Game-Changing Pancreatic Cancer Data.
Read More
Read More
Institutional Member News
New Clinical Trials Now Open at UC Davis Comprehensive Cancer Center:
MCLA-158-CL02 — Head & Neck
A Phase 3 randomized study evaluating petosemtamab versus investigator's choice monotherapy in patients with previously treated, incurable metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who have progressed on anti-PD-1 and platinum-based therapy.
BCA101X301 — Head & Neck
A Phase 2/3 randomized, double-blind study of ficerafusp alfa (BCA101), a dual EGFR/TGF-β targeting agent, in combination with pembrolizumab for first-line treatment of PD-L1-positive recurrent or metastatic HNSCC.
UCLA-L-11 — Thoracic
A Phase 2 trial evaluating ivonescimab, a monoclonal antibody, in patients with previously treated thymic carcinoma, measuring overall response rate, safety, and long-term outcomes including progression-free and overall survival.
ZL-1310-003 — Thoracic
A Phase 3 randomized study comparing ZL-1310, a DLL3 antibody-drug conjugate (ADC), to investigator's choice chemotherapy in patients with relapsed small cell lung cancer. Phase 1 data showed a 68% objective response rate and promising intracranial activity.
For referrals or more information, contact UC Davis Comprehensive Cancer Center's Office of Clinical Research at OCRReferral@health.ucdavis.edu or 916-382-6970.
